MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies
TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol "TNFA," effective before the market open on Wednesday, July 24, 2024.